Study on the impact of SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) on the bioavailability of ibandronate (IBN) in postmenopausal women

Journal of Drug Delivery Science and Technology

Volumn 21, Issue 6, 2011, Pages 521-525

  McIntyre, C ^a   Schmidt, J ^a   Castelli, M C ^b   Bittner, B ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b Clinical Development   (United States)

Author keywords

Absorption; Drug drug interaction; Ibandronate; SNAC

Indexed keywords

EXCIPIENT; IBANDRONIC ACID; SNAC (SODIUM N[8 (2 HYDROXYBENZOYL)AMINO]CAPRYLATE); UNCLASSIFIED DRUG;

ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; POSTMENOPAUSE; SINGLE DRUG DOSE;

EID: 84255171789     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(11)50084-X     Document Type: Article

References (21)

1. Chesnut III C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., Felsenberg D., Huss H., Gilbride J., Schimmer R.C., Delmas P.RD. - Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. - J. Bone Miner. Res., 19, 1241-1249, 2004. (Pubitemid 41094364)
2. Miller P.D., McClung M.R., Macovei L., Stakkestad J.A., Luckey M., Bonvoisin B., Reginster J.Y., Recker R.R., Hughes C., Lewiecki E.M., Felsenberg D., Delmas P.D., Kendler D.L., Bolognese M.A., Mairon N., Cooper C. - Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. - J. Bone Miner. Res., 20, 1315-1322, 2005. (Pubitemid 41033514)
3. Reginster J.-Y., Adami S, Lakatos P., Greenwald M., Stepan J.J., Silverman S.L., Christiansen C., Rowell L., Mairon N., Bonvoisin B., Drezner M.K., Emkey R., Felsenberg D., Cooper C., Delmas P.D., Miller P.D. - Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. - Ann. Rheum. Dis., 65, 654-61, 2006.
4. Barrett J., Worth E., Bauss F., Epstein S. - IBN: a clinical pharmacology and pharmacokinetic update. - J. Clin. Pharmacol., 44, 951-965, 2004.
5. Gonze M.D., Manord J.D., Leone-Bay A., Baughman R.A., Garrard C.L., Sternbergh W.C., Money S.R. - Orally administered heparin for preventing deep venous thrombosis. - A.J. Surgery, 176, 176-178, 1998. (Pubitemid 28420437)
6. Amidon G.L., Lennernas H., Shah V.P., Crison J.R. - A theoretical basis for a Biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. - Pharm. Res., 12, 413-420, 1995.
7. Lin J.H., Chen I.W., deLuna F.A. - On the absorption of alendronate in rats. - J. Pharm. Sci., 83, 1741-1746. 1994.
8. Lin J.H. - Bisphosphonates: a review of their pharmacokinetic properties. - Bone, 18, 75-85, 1996. (Pubitemid 26092586)
9. Boulenc X., Marti E., Joyeux H., Roques C., Berger Y., Fabre G. - Importance of the paracellular pathway for the transport of a new bisphosphonate using the human Caco-2 monolayers model. - Biochem. Pharmacol., 46, 1591-600, 1993. (Pubitemid 23338493)
10. Raiman J., Tormalehto S., Yritys K., Junginger H.E., Mönkkönen J. - Effects of various absorption enhancers on transport of clodronate through Caco-2 cells. - Int. J. Pharm., 261, 129-136, 2003. (Pubitemid 36962751)
11. Raiman J., Niemi R., Vepsalainen J., Yritys K., Jarvinen T., Mönkkönen J. - Effects of calcium and lipophilicity on transport of clodronate and its esters through Caco-2 cells. - Int. J. Pharm., 213, 135-142, 2001. (Pubitemid 32119469)
12. Wu S.J., Robinson J.R. - Transcellular and lipophilic complex-enhanced intestinal absorption of human growth hormone. - Pharm. Res., 16, 1266-1272, 1999.
13. Leone-Bay A., Sato M., Paton D., Hunt A.H., Sarubbi D., Carozza M., Chou J., McDonough J., Baughman R.A. - Oral delivery of biologically active parathyroid hormone. - Pharm. Res., 18, 964-970, 2001. (Pubitemid 32799941)
14. Ding X., Rath P., Angelo R., Stringfellow T., Flanders E., Dinh S., Gomez-Orellana I., Robinson J.R. - Oral absorption enhancement of cromolyn sodium through non covalent complexation. - Pharm. Res., 21, 2196-2206, 2004. (Pubitemid 40568433)
15. Leone-Bay A., Paton D.R., Variano B., Leipold H., Rivera T., Miura-Fraboni J., Baughman R., Santiago N. - Acylated non-alpha aminoacids as novel agents for the oral delivery of heparin sodium USP. - J. Control. Release, 50, 41-49, 1998. (Pubitemid 28044099)
16. Arbit E., Goldberg M., Gomez-Orellana I., Majuru S. - Oral heparin: status review. - Thrombosis J., 4, 1-7, 2006.
17. Brayden D., Creed E., O'Connell A., Leipod H., Agarwal R., Leone-Bay A. - Heparin absorption across the intestine: effects of sodium N-[8-(2- hydroxybenzoyl)amino]caprylate in rat in situ intestinal instillations and in caco-2 monolayers. - Pharm. Res., 14, 1772-1779, 2006.
18. Malkov D., Wang H.-Z., Dinh S., Gomez-Orellana I. - Pathway of oral absorption of heparin with sodium N-[8-(2-hydroxybenzoyl) amino]caprylate. - Pharm. Res., 19, 1180-1184, 2002. (Pubitemid 34985002)
19. Malkov D., Angelo R., Wang H.Z., Flanders E., Wang H., Gomez O.I. - Oral delivery of insulin with the eligen technology: mechanistic studies. - Curr. Drug Deliv., 2, 191-197, 2005. (Pubitemid 40488628)
20. Wu S.J., Robinson J.R. - Transport of human growth hormone across caco-2 cells with novel delivery agents: evidence for p-glycoprotein involvement. - J. Control. Release, 62, 171-177, 1999.
21. Alani A.W., Robinson J.R. - Mechanistic understanding of opral drug absorption enhancement of cromolyn sodium by an amino acid derivative. - Pharm. Res., 25, 48-54, 2008.